European Medicines Agency adopted a new indication for Bevacizumab

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation to the terms of the marketing authorization for the medicinal product Bevacizumab (Avastin). The CHMP adopted a new indication as follows: "Bevacizumab, in combination with carboplatin and gemcitabine, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with Bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents”. Read more here.